Extracorporeal photopheresis for the treatment of acute and chronic graft-versus-host disease in adults and children: Best practice recommendations from an Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and Italian Group for Bone Marrow Transplantation (GITMO) consensus process

Transfusion

Volumn 53, Issue 10, 2013, Pages 2340-2352

  Pierelli, Luca ^a   Perseghin, Paolo ^a   Marchetti, Monia ^a   Messina, Chiara ^a   Perotti, Cesare ^a   Mazzoni, Alessandro ^a   Bacigalupo, Andrea ^a   Locatelli, Franco ^a   Carlier, Paolo ^a   Bosi, Alberto ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

METHOXSALEN; STEROID;

ACUTE GRAFT VERSUS HOST DISEASE; ARTICLE; BLOOD TRANSFUSION; BLOOD VOLUME; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL PRACTICE; CONSENSUS; DAY HOSPITAL; EXTRACORPOREAL PHOTOPHERESIS; EYE; GASTROINTESTINAL TRACT; HEALTH CARE; HEALTH CARE COST; HEART TRANSPLANTATION; HEPATITIS C; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFORMED CONSENT; ITALIAN GROUP FOR BONE MARROW TRANSPLANTATION; ITALIAN SOCIETY OF HEMAPHERESIS AND CELL MANIPULATION; MEDICAL LITERATURE; MORTALITY; MOUTH MUCOSA; PHASE 2 CLINICAL TRIAL (TOPIC); PUVA; QUALITY OF LIFE; REDUCED INTENSITY CONDITIONING; STEM CELL TRANSPLANTATION; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW (TOPIC); T CELL DEPLETION; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; ULTRAVIOLET A RADIATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CONSENSUS; GRAFT VS HOST DISEASE; HUMANS; INFANT; INFANT, NEWBORN; ITALY; MIDDLE AGED; PHOTOPHERESIS; SOCIETIES, MEDICAL;

EID: 84885850726     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12059     Document Type: Article

References (82)

1. Devergie A,. Graft versus host disease. In:, Apperley J, Carreras E, Gluckman E, Gratwohl A, Masszi T, editors. EBMT-ESH handbook. Genoa, Italy: Forum Service Editore; 2008. p. 218-234.
2. Shang H, Chen J, Que W,. Allogeneic peripheral blood stem cell and bone marrow transplantation for hematologic malignancies: meta-analysis of randomized controlled trials. Leuk Res 2012; 36: 431-437.
3. Quellmann S, Schwarzer G, Hübel K, Greb A, Engert A, Bohlius J,. Corticosteroids for preventing graft-versus-host disease after allogeneic myeloablative stem cell transplantation. Cochrane Database Syst Rev 2008;(3): CD004885.
4. Salmasian H, Rohanizadegan M, Banihosseini S, Rahimi Darabad R, Rabbani-Anari M, Shakiba A, Ferrara JL,. Corticosteroid regimens for the treatment of acute and chronic graft-versus-host disease (GvHD) after allogeneic stem cell transplantation. Cochrane Database Syst Rev 2010;(1): CD005365.
5. Van Lint MT, Milone G, Leotta S, Uderzo C, Scimè R, Dall'Orso S, Locasciulli A, Guidi S, Mordini N, Sica S, Cudillo L, Fagioli F, Selleri C, Bruno B, Arcese W, Bacigalupo A,; for the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood 2006; 107: 4177-4181. (Pubitemid 43726830)
6. Choi SW, Levine JE, Ferrara JL,. Pathogenesis and management of graft-versus-host disease. Immunol Allergy Clin North Am 2010; 30: 75-101.
7. Marty FM, Lee SJ, Fahey MM, Alyea EP, Soiffer RJ, Antin JH, Baden LR,. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003; 102: 2768-2776. (Pubitemid 37258330)
8. Wolff D, Roessler V, Steiner B, Wilhelm S, Weirich V, Brenmoehl J, Leithaeuser M, Hofmeister N, Junghanss C, Casper J, Hartung G, Holler E, Freund M,. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept. Bone Marrow Transplant 2005; 35: 1003-1010. (Pubitemid 40711838)
9. Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, Litzow MR, Nieto Y, Savani BN, Schriber JR, Shaughnessy PJ, Wall DA, Carpenter PA,. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2012; 18: 1150-1163.
10. Pidala J, Kim J, Anasetti C,. Sirolimus as primary treatment of acute graft-versus-host disease following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009; 15: 881-888.
11. Bolaños-Meade J, Jacobsohn DA, Margolis J, Ogden A, Wientjes MG, Byrd JC, Lucas DM, Anders V, Phelps M, Grever MR, Vogelsang GB,. Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol 2005; 23: 2661-2668. (Pubitemid 46179455)
12. Jacobsohn DA, Chen AR, Zahurak M, Piantadosi S, Anders V, Bolaños-Meade J, Higman M, Margolis J, Kaup M, Vogelsang GB,. Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease. J Clin Oncol 2007; 25: 4253-4426.
13. Wolff D, Gerbitz A, Ayuk F, Kiani A, Hildebrandt GC, Vogelsang GB, Elad S, Lawitschka A, Socie G, Pavletic SZ, Holler E, Greinix H,. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant 2010; 16: 1611-1628.
14. Wolff D, Schleuning M, von, Harsdorf S, Bacher U, Gerbitz A, Stadler M, Ayuk F, Kiani A, Schwerdtfeger R, Vogelsang GB, Kobbe G, Gramatzki M, Lawitschka A, Mohty M, Pavletic SZ, Greinix H, Holler E,. Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2011; 17: 1-17.
15. Bladon J, Taylor PC,. Extracorporeal photopheresis induces apoptosis in the lymphocytes of cutaneous T-cell lymphoma and graft-versus-host disease patients. Br J Haematol 1999; 107: 707-711. (Pubitemid 30020139)
16. Klassen J,. The role of photopheresis in the treatment of graft-versus-host disease. Curr Oncol 2010; 17: 53-58.
17. Biagi E, Di Biaso I, Leoni V, Gaipa G, Rossi V, Bugarin C, Renoldi G, Parma M, Balduzzi A, Perseghin P, Biondi A,. Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+Foxp3+CD62L+ functional regulatory T-cells in patients with graft-versus-host disease. Transplantation 2007; 84: 31-39. (Pubitemid 47094638)
18. De Silvestro G, Bagatella P, Vicarioto M, Tison T, Marson P,. The Italian SIdEM registry for apheresis: an overview of the 2005 statistics. Int J Artif Organs 2008; 31: 352-362.
19. Flowers ME, Apperley JF, van, Besien K, Elmaagacli A, Grigg A, Reddy V, Bacigalupo A, Kolb HJ, Bouzas L, Michallet M, Prince HM, Knobler R, Parenti D, Gallo J, Greinix HT,. A multi center prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic GVHD. Blood 2008; 112: 2667-2673.
20. Greinix HT, van Besien K, Elmaagacli AH, Hillen U, Grigg A, Knobler R, Parenti D, Reddy V, Theunissen K, Michallet M,; Flowers ME for the UVADEX Chronic GVHD Study Group. Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis-results of a crossover randomized study. Biol Blood Marrow Transplant 2011; 17: 1775-1782.
21. Sher GD, Devine DV,. The consensus development process in transfusion medicine: does it add value? Transfusion 2007; 47: 2176-2179. (Pubitemid 350151217)
22. Williams PL, Webb C,. The Delphi technique: a methodological discussion. J Adv Nurs 1994; 19: 180-186.
23. Jones J, Hunter D,. Consensus methods for medical and health services research. Br Med J 1995; 311: 376-380.
24. Greinix HT, Volc-Platzer B, Kalhs P, Fisher G, Rosenmayr A, Keil F, Hönigsmann H, Knobler RM,. Extracoporeal photochemotherapy in the treatment of severe steroid-refactory acute graft-versus-host disease: a pilot study. Blood 2000; 96: 2426-2431.
25. Messina C, Locatelli F, Lanino E, Uderzo C, Zacchello G, Cesaro S, Pillon M, Perotti C, Del Fante C, Faraci M, Rivabella L, Calore E, De Stefano P, Zecca M, Giorgiani G, Brugiolo A, Balduzzi A, Dini G, Zanesco L, Dall'Amico R,. Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. Br J Haematol 2003; 122: 118-127. (Pubitemid 36819346)
26. Kanold J, Messina C, Halle P, Locatelli F, Lanino E, Cesaro S, Deméocq F,; Paediatric Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Update on extracorporeal photochemotherapy for graft-versus-host disease treatment. Bone Marrow Transplant 2005; 35 (Suppl. 1): S69-S71. (Pubitemid 40613927)
27. Garban F, Drillat P, Makowski C, Jacob MC, Richiard MJ, Favrot M, Sotto JJ, Bensa JC, Cahn JY,. Extracorporeal chemophototherapy for the treatment of graft-versus-host disease: hematologic consequences of short-term, intensive courses. Haematologica 2005; 90: 1096-1101. (Pubitemid 41323509)
28. Greinix HT, Knobler RM, Worel N, Schneider B, Schneeberger A, Hoecker P, Mitterbauer M, Rabitsch W, Schulenburg A, Kahls P,. The effect of intensified photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica 2006; 91: 405-408.
29. Berger M, Pessolano R, Albiani R, Asaftei S, Barat V, Carraro F, Biasin E, Madon E, Fagioli F,. Extracorporeal photopheresis for steroid resistant graft versus host disease in pediatric patients: a pilot single institution report. J Pediatr Hematol Oncol 2007; 29: 678-687.
30. Kanold J, Merlin E, Halle P, Paillard C, Marabelle A, Rapatel C, Evrard B, Berger C, Stephan JL, Galambrun C, Piguet C, D'Incan M, Bordigoni P, Deméocq F,. Photopheresis in pediatric graft-versus-host disease after allogeneic marrow transplantation: clinical practice guidelines based on field experience and review of the literature. Transfusion 2007; 47: 2276-2289. (Pubitemid 350151207)
31. Perfetti P, Carlier P, Strada P, Gualandi F, Occhini D, Van Lint MT, Ibatici A, Lamparelli T, Bruno B, Raiola AM, Dominietto A, Di Grazia C, Bregante S, Zia S, Ferrari GM, Stura P, Pogliani E, Bacigalupo A,. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. Bone Marrow Transplant 2008; 42: 609-617.
32. Calore E, Cala A, Tridello G, Cesaro S, Pillon M, Varotto S, Gazzola MV, Destro R, Marson P, Trentin L, Carli M, Messina C,. Extracorporeal photochemotherapy may improve outcome in children with acute GVHD. Bone Marrow Transplant 2008; 42: 421-425.
33. Merlin E, Paillard C, Rochette E, David A, Isfan F, Doré E, Deméocq F, Kanold J,. Extracorporeal photochemotherapy as second- or first-line therapy of acute GVHD? Bone Marrow Transplant 2010; 45: 963-965.
34. Perotti C, Del Fante C, Tinelli C, Viarengo G, Scudeller L, Zecca M, Locatelli F, Salvaneschi L,. Extracorporeal photochemotherapy in graft-versus-host disease: a longitudinal study on factors influencing the response and survival in pediatric patients. Transfusion 2010; 50: 1359-1369.
35. Hildebrandt GC, Fazekas T, Lawitschka A, Bertz H, Greinix H, Halter J, Pavletic SZ, Holler E, Wolff D,. Diagnosis and treatment of pulmonary chronic GvHD: report from the consensus conference on clinical practice in chronic GvHD. Bone Marrow Transplant 2011; 46: 1283-1295.
36. Deeg HJ,. How I treat refractory acute GVHD. Blood 2007; 109: 4119-4126. (Pubitemid 46743372)
37. Urbani L, Mazzoni A, Colombatto P, Bindi L, Biancofiore G, Tascini C, Menichetti F, Brunetto MR, Scatena F, Filipponi F,. A novel immunosuppressive strategy combined with pre-emptive antiviral therapy improves the eighteen-month mortality in HCV recipients transplanted with aged livers. Transplantation 2008; 86: 1066-1107.
38. Smith EP, Sniecinski I, Dagis AC, Parker PM, Snyder DS, Stein AS, Nademanee A, O'Donnell MR, Molina A, Schmidt GM, Stepan DE, Kapoor N, Niland JC, Forman SJ,. Extracorporeal photochemotherapy for treatment of drug-resistant graft-vs.-host disease. Biol Blood Marrow Transplant. 1998; 4: 27-37. (Pubitemid 128538798)
39. Greinix HT, Volc-Platzer B, Rabitsch W, Gmeinhart B, Guevara-Pineda C, Kalhs P, Krutmann J, Hönigsmann H, Ciovica M, Knobler RM,. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 1998; 92: 3098-3104. (Pubitemid 28492315)
40. Zic JA, Miller JL, Stricklin GP, King LE,. The North American experience with photopheresis. Ther Apher 1999; 3: 50-62. (Pubitemid 29133871)
41. Child FJ, Ratnavel R, Watkins P, Samson D, Apperley J, Ball J, Taylor P, Russell-Jones R,. Extracorporeal photopheresis (ECP) in the treatment of chronic graft-versus-host disease (GVHD). Bone Marrow Transplant 1999; 23: 881-887. (Pubitemid 29213689)
42. Salvaneschi L, Perotti C, Zecca M, Bernuzzi S, Viarengo G, Giorgiani G, Del Fante C, Bergamaschi P, Maccario R, Pession A, Locatelli F,. Extracorporeal photochemotherapy for treatment of acute and chronic GVHD in childhood. Transfusion 2001; 41: 1299-1305. (Pubitemid 33000969)
43. Apisarnthanarax N, Donato M, Korbling M, Couriel D, Gajewski J, Giralt S, Khouri I, Hosing C, Champlin R, Duvic M, Anderlini P,. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Bone Marrow Transplant 2003; 31: 459-465. (Pubitemid 36511812)
44. Seaton ED, Szydlo RM, Kanfer E, Apperley JF, Russell-Jones R,. Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of response. Blood 2003; 102: 1217-1223. (Pubitemid 36988025)
45. Rubegni P, Cuccia A, Sbano P, Cevenini G, Carcagnì MR, D'Ascenzo G, De Aloe G, Guidi S, Guglielmelli P, Marotta G, Lauria F, Bosi A, Fimiani M,. Role of extracorporeal photochemotherapy in patients with refractory chronic graft-versus-host disease. Br J Haematol 2005; 130: 271-275. (Pubitemid 41602528)
46. Foss FM, Di Venuti GM, Chin K, Sprague K, Grodman H, Klein A, Chan G, Stiffler K, Miller KB,. Prospective study of extracorporeal photopheresis in steroid-refractory or steroidresistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors. Bone Marrow Transplant 2005; 35: 1187-1193. (Pubitemid 40895175)
47. Bisaccia E, Palangio M, Gonzalez J, Adler KR, Scarborough R, Goldberg SL, Rowley SD,. Treatment of extensive chronic graft-versus-host disease with extracorporeal photochemotherapy. J Clin Apher 2006; 21: 181-187. (Pubitemid 46579293)
48. Couriel DR, Hosing C, Saliba R, Shpall EJ, Anderlini P, Rhodes B, Smith V, Khouri I, Giralt S, de, Lima M, Hsu Y, Ghosh S, Neumann J, Andersson B, Qazilbash M, Hymes S, Kim S, Champlin R, Donato M,. Photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood 2006; 107: 3074-3080.
49. Perseghin P, Galimberti S, Balduzzi A, Bonanomi S, Baldini V, Rovelli A, Dassi M, Rambaldi A, Castagna L, Corti P, Pogliani EM, Uderzo C,. Extracorporeal photochemotherapy for the treatment of chronic graft-versus-host disease: trend for a possible cell dose-related effect? Ther Apher Dial 2007; 11: 85-93. (Pubitemid 46449867)
50. Dignan FL, Greenblatt D, Cox M, Cavenagh J, Oakervee H, Apperley JF, Fielding AK, Pagliuca A, Mufti G, Raj K, Marks DI, Amrolia P, Peniket A, Medd P, Potter MN, Shaw BE, Scarisbrick JJ,. Efficacy of bimonthly extracorporeal photopheresis in refractory chronic mucocutaneous GVHD. Bone Marrow Transplant 2012; 47: 824-830.
51. Del Fante C, Scudeller L, Viarengo L, Bernasconi P, Perotti C,. Response and survival of patients with chronic graft-versus-host disease treated by extracorporeal photochemotherapy: a retrospective study according to classical and National Institutes of Health classifications. Transfusion 2012; 52: 2007-2015.
52. Jagasia MH, Savani BN, Stricklin G, Engelhardt B, Kassim A, Dixon S, Chen H, Chinratanalab W, Goodman S, Greer JP, Schuening F,. Classic and overlap chronic graft-versus-host disease (cGVHD) is associated with superior outcome after extracorporeal photopheresis (ECP). Biol Blood Marrow Transplant 2009; 15: 1288-1295.
53. Akhtari M, Giver CR, Ali Z, Flowers CR, Gleason CL, Hillyer CD, Kaufman J, Khoury HJ, Langston AA, Lechowicz MJ, Lonial S, Renfroe HM, Roback JD, Tighiouart M, Vaughn L, Waller EK,. Receiver operating characteristic curve analysis of circulating blood dendritic cell precursors and T cells predicts response to extracorporeal photopheresis in patients with chronic graft-versus-host disease. Transfusion 2010; 50: 2424-2431.
54. O'Brien PJ, Bolwell B, Abhyankar S, Shaughnessy P, Williamson P, Campbell KA,. Pre-transplant biomarkers predict GVHD and treatment-related mortality in patients treated with extracorporeal photopheresis prior to allogeneic bone-marrow transplantation. Biol Blood Marrow Transplant 2007; 13: 115.
55. Braamse AM, Gerrits MM, van, Meijel B, Visser O, van, Oppen P, Boenink AD, Cuijpers P, Huijgens PC, Beekman AT, Dekker J,. Predictors of health-related quality of life in patients treated with auto- and allo-SCT for hematologic malignancies. Bone Marrow Transplant 2012; 47: 757-769.
56. Lee SJ, Kim HT, Ho VT, Cutler C, Alyea EP, Soiffer RJ, Antin JH,. Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant 2006; 38: 305-310. (Pubitemid 44203780)
57. Pidala J, Kurland B, Chai X, Majhail N, Weisdorf DJ, Pavletic S, Cutler C, Jacobsohn D, Palmer J, Arai S, Jagasia M, Lee SJ,. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood 2011; 117: 465-467.
58. Caocci G, Efficace F, Ciotti F, Roncarolo MG, Vacca A, Piras E, Littera R, Dawood Markous RS, Collins GS, Ciceri F, Mandelli F, Marktel S, La Nasa G,. Prospective assessment of health-related quality of life in pediatric patients with beta-thalassemia following hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011; 17: 861-866.
59. Pallua S, Giesinger J, Oberguggenberger A, Kemmler G, Nachbaur D, Clausen J, Kopp M, Sperner-Unterweger B, Holzner B,. Impact of GvHD on quality of life in long-term survivors of haematopoietic transplantation. Bone Marrow Transplant 2010; 45: 1514-1519.
60. Chiodi S, Spinelli S, Ravera G, Petti AR, Van Lint MT, Lamparelli T, Gualandi F, Occhini D, Mordini N, Berisso G, Bregante S, Frassoni F, Bacigalupo A,. Quality of life in 244 recipients of allogeneic bone marrow transplantation. Br J Haematol 2000; 110: 614-619.
61. Barr ML, Meiser BM, Eisen HJ, Roberts RF, Livi U, Dall'Amico R, Dorent R, Rogers JG, Radovancevic̈ B, Taylor DO, Jeevanandam V, Marboe CC,. Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group. N Engl J Med 1998; 339: 1744-1751. (Pubitemid 28555433)
62. Marques MB, Schwartz J,. Update on extracorporeal photopheresis in heart and lung transplantation. J Clin Apher 2011; 26: 146-151.
63. Shaughnessy PJ, Bolwell BJ, van, Besien K, Mistrik M, Grigg A, Dodds A, Prince HM, Durrant S, Ilhan O, Parenti D, Gallo J, Foss F, Apperley J, Zhang MJ, Horowitz MM, Abhyankar S,. Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2010; 45: 1068-1076.
64. Schneiderman J, Duerst R, Campbell K, Krutsick A, Tse W, Thormann K, Kletzel M, Jacobsohn DA,. Reduced intensity conditioning (RIC) and hematopoietic stem cell transplantation (HSCT) utilizing extracorporeal photopheresis (ECP), fludarabine and targeted dose busulfan in children. Blood 2006; 108: 418B-419.
65. Chan GW, Foss FM, Klein AK, Sprague K, Miller KB,. Reduced-intensity transplantation for patients with myelodisplastic syndrome achieves durable remission with less graft-versus-host disease. Biol Blood Marrow Transplant 2003; 9: 753-759. (Pubitemid 38145744)
66. Liesveld JL, Abboud CN, Bernestein SH, Friedberg J, Ifthikharuddin JJ, Constine LS, Kaplan KL, Wedow NP, Nichols DD, Oliva J, Etter M, Phillips GL,. Extracorporeal photopheresis, pentostatin, and TBI for reduced-intensity preparation: adaptation of the Tufts experience at a single transplant center. Blood 2005; 106: 440B.
67. Witt V, Stegmayr B, Ptak J, Wikstrom B, Berlin G, Axelsson CG, Griskevicius A, Centoni PE, Liumbruno GM, Molfettini P, Audzijoniene J, Mokvist K, Sojka BN, Norda R, Ramlow W, Blaha M, Evergren M, Tomaz J,. World apheresis registry data from 2003 to 2007, the pediatric and adolescent side of the registry. Transfus Apher Sci 2008; 39: 253-260.
68. McLeod BC, Szczepiorkowski ZM, Weinstein R, Winters JL,. Apheresis: principles and practice. 3rd ed. Bethesda (MD): American Association of Blood Banks Press; 2010.
69. Hackstein H, Misterek J, Nockher A, Reiter A, Bein G, Woessmann W,. Mini buffy coat photopheresis for children and critically ill patients with extracorporeal photopheresis contraindications. Transfusion 2009; 49: 2366-2373.
70. Bisaccia E, Vonderheld EC, Geskin L,. Safety of a new, single, integrated, closed photopheresis system in patients with cutaneous T-cell lymphoma. Br J Dermatol 2009; 161: 167-169.
71. Schooneman F,. Extracorporeal photopheresis technical aspects. Transfus Apher Sci 2003; 28: 51-61. (Pubitemid 36298591)
72. Perseghin P, Incontri A,. Mononuclear cell collection in patients treated with extracorporeal photochemotherapy by using the off-line method: a comparison between COBE Spectra AutoPbsc version 6.1 and Amicus cell separators. J Clin Apher 2010; 25: 310-314.
73. Heshmati F,. Mechanisms of action of extracorporeal photochemotherapy. Transfus Apher Sci 2003; 29: 61-70. (Pubitemid 36873797)
74. Heshmati F,. Extracorporeal photo chemotherapy (ECP) in acute and chronic GVHD. Transfus Apher Sci 2010; 43: 211-215.
75. Perseghin P,. Extracorporeal photochemotherapy as a challenging treatment for cutaneous T-cell lymphoma, acute and chronic graft-versus-host disease, organ rejection and T-lymphocyte-mediated autoimmune diseases. Transfus Med Hemother 2008; 35: 8-17. (Pubitemid 351252952)
76. Saito AM, Cutler C, Zahrier D, Soiffer RJ, Ho VT, Alyea EP, Koreth J, Antin JH, Lee SJ,. Costs of hematopoietic cell transplantation with high-dose regimens. Biol Blood Marrow Transplant 2008; 14: 197-207.
77. Lee SJ, Zahrier D, Alyea EP, Weller E, Ho VT, Antin JH, Soiffer RJ,. Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for haematologic diseases: clinical outcomes, quality of life, costs. Blood 2002; 100: 2697-2702.
78. ECP NORCOM Policy Development Group. A review of extracorporeal photopheresis for cancer and other diseases-version 3. 2008. [cited 2011 Dec]. Available from: URL: http://www.sheffield.nhs.uk/policies/resources/norcom/ extracorporealphotopheresisforcancer.pdf
79. Ilhan O, Arat M, Arslan O, Ayyildiz E, Sanli H, Beksac M, Ozcan M, Gürman G, Akan H,. Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft-versus-host disease. Transfus Apher Sci 2004; 30: 185-187. (Pubitemid 38698331)
80. Wong FL, Francisco L, Togawa K, Bosworth A, Gonzales M, Hanby C, Sabado M, Grant M, Forman SJ, Bhatia S,. Long-term recovery after hematopoietic cell transplantation: predictors of quality-of-life concerns. Blood 2010; 115: 2508-2519.
81. Pidala J, Anasetti C, Khardan-Dabaia MA, Cutler C, Sheldon A, Djulbegovic B,. Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation. Biol Bone Marrow Transplant 2009; 15: 1415-1421.
82. Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Weinstein R, Shaz BH,; Apheresis Applications Committee of the American Society for Apheresis. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2010; 25: 83-177.